Deal activity by volume related to ESG increased by 86% year-on-year in 2022 in the medical industry

Analysis of the key themes driving deal activity reveals that ESG accounted for 314 pharmaceutical deals between 2018 and 2022, worth a total value of $131,024m, according to GlobalData’s Deals database Analysis of the key themes driving deal activity reveals that ESG accounted for 126 medical deals between 2018 and 2022, worth a total value of $11,095m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships. The $75m venture financing issue by RapidSOS was the largest disclosed deal in 2022, while the $15m venture financing issue by Hemanext was the largest disclosed deal in 2021.  

In volume terms, ESG-related deal activity increased by 86% year-on-year in 2022, whereas it decreased by 83% year-on-year in 2021.  

Partnerships accounted for the highest number of deals in the last five years, with 41 deals, followed by venture financing (27 deals) and acquisitions (21 deals).

The top financial advisors supporting deals related to ESG in the medical industry in the last five years in terms of value were Goldman Sachs International, Barclays Wealth Management, Deutsche Bank, J.P. Morgan Cazenove, and Rothschild.

The top legal advisors supporting deals related to ESG in the medical industry in the last five years in terms of value were Allen & Overy, Arnold & Porter Kaye Scholer, Shearman & Sterling, Simpson Thacher & Bartlett, and Travers Smith.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements. 

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.